Table 1.
Baseline patient characteristics (N=470)
| Patients, n (%) | mRCC cohort | mUC cohort | |
| Total | |||
| (N=470) | (N=271) | (N=199) | |
| Age at start of ICI (years) | |||
| Mean (SD) | 64.8 (11.6) | 61.7 (10.9) | 69.0 (11.1) |
| Median (min, max) | 65 (22 to 91) | 62 (22 to 85) | 69 (26 to 91) |
| Sex | |||
| Male | 342 (72.8) | 201 (74.2) | 141 (70.9) |
| Female | 128 (27.2) | 70 (25.8) | 58 (29.2) |
| Line of ICI | |||
| First | 207 (44.0) | 113 (41.7) | 94 (47.2) |
| Second or more | 263 (56.0) | 158 (58.3) | 105 (52.8) |
| ECOG PS | |||
| 0 | 149 (32.4) | 78 (28.8) | 71 (37.6) |
| 1 | 242 (52.6) | 156 (57.6) | 86 (45.5) |
| 2 | 65 (14.1) | 37 (13.7) | 28 (14.8) |
| 3 | 4 (0.9) | _ | 4 (2.1) |
| Site of metastasis | |||
| Lung | 257 (54.7) | 176 (64.9) | 81 (40.7) |
| Lymph nodes | 393 (83.6) | 211 (77.9) | 182 (91.5) |
| Bone | 119 (25.3) | 81 (29.9) | 38 (19.1) |
| Liver | 112 (23.8) | 67 (24.7) | 45 (22.6) |
| Brain | 14 (3.0) | 12 (4.4) | 2 (1.0) |
| Other | 104 (63.8) | 104 (38.4) | 59 (29.7) |
| Type of ICI | |||
| PD-1 inhibitors* | 312 (66.2) | 197 (72.7) | 114 (57.3) |
| PD-L1 inhibitors† | 159 (33.8) | 74 (27.3) | 85 (42.7) |
| ICI type | |||
| ICI monotherapy | 341 (72.5) | 157 (57.9) | 184 (92.5) |
| ICI+ICI | 43 (9.2) | 30 (11.1) | 13 (6.5) |
| ICI+other‡ | 86 (18.3) | 84 (31.0) | 2 (1.0) |
*Includes pembrolizumab and nivolumab.
†Includes atezolizumab, avelumab, and durvalumab.
‡Investigational immunotherapy and targeted therapy agents.
ICI, immune checkpoint inhibitor; mRCC, metastatic renal cell carcinoma; mUC, metastatic urothelial carcinoma; PD-1, programmed cell death protein 1; PD-L1, programmed cell death ligand 1; ECOG PS, Eastern Cooperative Oncology Group Performance Status.